ISSN: 2536-7153 SJMLS

Sokoto Journal of Medical Laboratory Science 2024; 9(4): 135 - 144

SJMLS - 9(4) - 016

Artificial Blood Substitutes: An Update on Strategies For Blood Transfusion Alternatives

Moore-Igwe, B.W. [1]* and Wenah-Emmanuel, J.E.[2]
Department of Haematology and Blood Transfusion and Science, Rivers State University, Port-Harcourt, Nigeria [1], Department of Haematology and Blood Transfusion, University of Port Harcourt Teaching Hospital (UPTH) [2]

Author for Correspondence*: beatrice.moore-igwe1@ust.edu.ng
https://dx.doi.org/10.4314/sokjmls.v9i4.16

Summary
The ongoing challenges in blood donation, storage, and transfusion have underscored the need for effective alternatives to regular blood products. This review provides a comprehensive overview of artificial blood substitutes, highlighting their historical development, current advancements, and future directions. Blood transfusions carry inherent risks, including infections and compatibility issues, leading to an increased demand for safe and efficient substitutes. Early attempts at blood replacement have evolved into sophisticated products, including perfluorocarbon (PFC) emulsions, haemoglobin-based oxygen carriers (HBOCs), and stem cell-derived blood products. Each type exhibits unique mechanisms of oxygen transport, along with advantages and limitations concerning safety, efficacy, and stability. Recent clinical trials have demonstrated varying degrees of success and challenges in the application of these substitutes in real-world settings, particularly in trauma and surgical contexts. However, issues related to toxicity, regulatory hurdles, and production costs remain significant barriers to widespread adoption. The integration of bioengineering and nanotechnology has the potential to enhance the functionality of artificial blood products, while advances in gene editing and molecular techniques could pave the way for personalized blood substitutes tailored to individual patient needs. As research progresses, it is imperative to address the existing challenges to optimize artificial blood substitutes for clinical use. This review concludes by emphasizing the need for ongoing research and innovation to fully realize the potential of these alternatives, which could transform transfusion medicine and improve patient outcomes.

Keywords: Artificial blood substitutes, bioengineering, hemoglobin-based oxygen carriers, perfluorocarbon emulsions, transfusion medicine.

1.0 Introduction

The demand for blood transfusion is constantly rising due to increased surgical procedures, trauma care, cancer treatments, and the aging population. However, the supply of donated blood is limited, exacerbated by the short shelf-life of stored blood, donor shortages, and logistical challenges in storage and transportation, particularly in remote or resource-limited areas. These limitations make it increasingly difficult to maintain an adequate supply of blood for transfusion, leading to significant gaps in life-saving treatment options globally (Riess, 2018).

Moreover, blood transfusion is not without risks. Transfused blood carries the potential for transmission of infections such as hepatitis B, hepatitis C, and HIV, despite advances in screening and testing techniques. Incompatibility reactions, such as hemolytic transfusion reactions, can also occur, particularly in emergency settings where blood typing and cross-matching may be rushed or unavailable (Spahn and Kocian, 2020). Other complications, including transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO), further emphasize the need

for safer alternatives to traditional blood transfusion (Silverman and Weiskopf, 2021).

The growing demand for viable alternatives to donated blood has led to extensive research into artificial blood substitutes. These substitutes aim to overcome the limitations of donated blood by providing a reliable, safe, and readily available source of oxygen carriers or blood volume expanders that can be stored for longer periods and are free from the risks of infection and immune reactions (Jahr *et al*., 2019). Advancements in the field have focused on the development of hemoglobin-based oxygen carriers (HBOCs), perfluorocarbon-based oxygen carriers (PFCs), and stem-cell-derived blood products, each with its own set of potential benefits and challenges (Winslow,2020).

This review aims to provide an update on recent advancements in artificial blood substitutes. By examining key developments in haemoglobin-based, perfluorocarbon-based, and other innovative blood substitute technologies, this review seeks to highlight the potential these alternatives hold in addressing current challenges in blood donation and transfusion. Additionally, it will explore the clinical implications of artificial blood substitutes, their safety profiles, and future directions for research in this field.

2.1 Historical Overview of Blood Substitutes

2.1.1 Early Attempts at Blood Replacement

The quest for blood replacement began as early as the 17th century, with the first recorded blood transfusion performed in 1667 by Jean-Baptiste Denis, a French physician who transfused lamb's blood into a human to cure mental illness. The procedure resulted in fatal complications due to immune reactions, as the science of blood compatibility had not yet been discovered (Chang, 2018). Throughout the 18th and 19th centuries, several attempts were made to replace human blood with other fluids, including milk, saline, and even beer, though these substitutes failed to mimic the vital functions of blood, especially oxygen transport (Hess and Thomas, 2019).

By the mid-19th century, blood transfusions from human to human became more common, particularly during wartime when trauma care demanded solutions for severe blood loss. However, transfusions were still fraught with dangers, including incompatibility reactions and infections (Pan *et al.,*2023). The discovery of blood types by Karl Landsteiner in 1901 was a significant milestone, reducing the risks associated with blood transfusion by introducing the concept of blood matching (Parapia, 2010).

2.1.2 Evolution of Artificial Blood Research

The modern era of artificial blood research began in the 20th century, when researchers sought to develop oxygen-carrying solutions to replace or supplement human blood. Early work focused on haemoglobin-based oxygen carriers (HBOCs), given haemoglobin's natural role in oxygen transport. Isolated hemoglobin from human or animal sources was modified and used as a blood substitute, but early HBOCs faced significant issues, including rapid breakdown in the body, oxidative stress, and vasoconstriction, which limited their clinical utility (Schmidt, 2019).

Simultaneously, research into perfluorocarbons (PFCs), synthetic compounds with high oxygen and carbon dioxide solubility, began to gain attention. PFCs offered a non-biological alternative to red blood cells, with the ability to carry oxygen in dissolved form. Clinical trials of PFCs were conducted in the 1980s and 1990s, but issues such as the need for emulsification, limited oxygen transport efficiency, and side effects like flu-like symptoms hindered their widespread adoption (Hillyer *et al.,* 2021).

The late 20th and early 21st centuries saw considerable advancements in the field, with scientists focusing on overcoming the limitations of earlier products. Innovations such as hemoglobin encapsulation, polymerization, and recombinant technology have improved the safety profiles of HBOCs by reducing toxicity and prolonging circulation time (Jahr and Walker, 2022). In addition, the exploration of stem cell technologies and gene editing has introduced the potential for producing red blood cell substitutes at scale, which could eventually provide an unlimited source of blood for transfusion (Riess, 2021). These advancements mark significant progress toward the

development of effective artificial blood substitutes, though challenges remain before they can fully replace donated blood in clinical practice.

2.2 Types of Artificial Blood Substitutes

1. **Perfluorocarbon (PFC) Emulsions**
   Perfluorocarbon (PFC) emulsions are synthetic compounds that are capable of carrying and delivering oxygen. PFCs are chemically inert and can dissolve large amounts of oxygen and other gases. These emulsions transport oxygen by dissolving it in the liquid phase, which allows them to deliver oxygen efficiently to tissues that require it (Riess, 2018). Unlike red blood cells, which rely on hemoglobin to transport oxygen, PFCs carry oxygen directly. This property makes PFCs useful in situations where traditional blood transfusions might not be possible or practical (Spahn and Kocian, 2020).

   Current research has demonstrated the potential of PFC emulsions in trauma, surgery, and respiratory disorders, particularly where oxygen delivery is compromised. PFC emulsions have several advantages, including long shelf life, no need for blood typing, and minimal risk of immunogenic reactions (Silverman and Weiskopf, 2021). However, the clinical application of PFC emulsions is limited by their relatively low oxygen-carrying capacity and the need for patients to receive supplemental oxygen during treatment (Jahr and Walker, 2019).

2. **Haemoglobin-Based Oxygen Carriers (HBOCs)**
   Haemoglobin-based oxygen carriers (HBOCs) are designed to mimic the oxygen-carrying function of natural haemoglobin found in red blood cells. These substitutes are made from human or animal haemoglobin or synthesized using recombinant technologies. HBOCs transport oxygen by binding it to the heme group of the hemoglobin molecule, releasing oxygen as needed (Winslow, 2020).

   There are two main approaches in HBOC development: chemical modification and recombinant production. Chemical modifications such as cross-linking or polymerization enhance the stability of free hemoglobin in circulation. Recombinant techniques allow for the design of hemoglobin molecules with specific properties to improve oxygen transport and reduce side effects (Chang, 2018). Despite these advancements, HBOCs have faced significant clinical challenges, including toxicity due to oxidative stress and vasoconstriction caused by free hemoglobin. These issues have led to the failure of many HBOCs in clinical trials, though efforts continue to refine the technology (Hess and Thomas, 2019).

3. **Stem Cell-Derived Blood Products**
   Stem cell-derived blood products offer an innovative solution to the problem of blood supply shortages. Researchers have developed methods to generate red blood cells from stem cells, including induced pluripotent stem cells (iPSCs) and hematopoietic stem cells (Pan *et al*.,2023). These lab-grown red blood cells could provide a virtually unlimited source of oxygen carriers, reducing the reliance on donor blood and eliminating the risk of transfusion-transmitted infections and immune reactions (Parapia, 2020).

   However, significant challenges remain in scaling up the production of stem cell-derived red blood cells to meet clinical demand. Current methods are expensive, time-consuming, and difficult to scale for large-scale production (Schmidt, 2019). Additionally, ensuring that the lab-grown cells are functional and safe in the human body is an ongoing area of research.

3. **Synthetic Oxygen Carriers**
   The development of synthetic oxygen carriers, including nanoparticles, represents a promising alternative to both PFC emulsions and HBOCs. Nanoparticles can be engineered to deliver oxygen efficiently and with fewer side effects than traditional carriers. These carriers can be designed to mimic red blood cells or other oxygen-transport systems (Hillyer *et al*.,2021).

Synthetic oxygen carriers have several advantages over conventional blood substitutes, including stability, long shelf life, and the ability to be produced without reliance on donor blood. They also avoid many of the complications associated with HBOCs, such as toxicity and oxidative stress. Although these technologies are still in the experimental phase, they hold significant promise for applications in trauma, surgery, and emergency care (Riess, 2021).

2.3 Challenges in Developing Artificial Blood Substitutes

The development of artificial blood substitutes, while promising, faces several critical challenges that must be addressed before widespread clinical use can be achieved. These challenges range from safety concerns to production scalability, each presenting unique obstacles for researchers and manufacturers.

1. **Safety and Toxicity Issues**

   One of the most significant challenges in the development of artificial blood substitutes is ensuring their safety. Many artificial blood substitutes, especially hemoglobin-based oxygen carriers (HBOCs), have been associated with toxicity issues such as oxidative stress and vasoconstriction (Spahn and Kocian, 2020). Free hemoglobin, which is a key component in HBOCs, can scavenge nitric oxide, leading to vasoconstriction and hypertension. Additionally, oxidative damage caused by free radicals can harm tissues, limiting the therapeutic potential of these substitutes (Riess, 2018).

   Researchers are exploring various strategies to mitigate these issues, including modifying the structure of hemoglobin and using encapsulation techniques to prevent hemoglobin from interacting directly with blood vessels (Silverman and Weiskopf,2021). However, achieving an ideal balance between oxygen delivery and minimizing toxicity remains an ongoing challenge.

2. **Stability, Storage, and Shelf Life**

   Another major challenge for artificial blood substitutes is ensuring long-term stability and an extended shelf life. Natural blood has limited shelf life due to the degradation of red blood cells, but artificial substitutes, such as PFC emulsions and synthetic oxygen carriers, need to maintain their efficacy during storage. Maintaining the stability of these substitutes is particularly important in emergency situations and in areas with limited access to refrigeration (Jahr and Walker, 2019).

   Moreover, some artificial blood products require specific storage conditions or additives to maintain their stability, which can complicate their use in resource-limited settings. Addressing these challenges is critical to ensuring that artificial blood substitutes can be deployed effectively in clinical practice.

3. **Regulatory Hurdles and Approval Process**

   The regulatory approval process for artificial blood substitutes has been particularly challenging due to the stringent safety standards required for blood products. Given the risks associated with blood substitutes, such as toxicity and immune reactions, regulatory agencies such as the U.S. Food and Drug Administration (FDA) have set high safety and efficacy benchmarks (Winslow, 2020). These standards, while necessary for patient safety, have contributed to delays in the approval of many promising artificial blood substitutes.

   Several products have failed to meet these regulatory standards due to insufficient data on long-term safety, particularly in relation to toxicity and side effects (Chang, 2018). Additionally, clinical trials for artificial blood products are complex and expensive, which poses a significant barrier to smaller companies developing these products (Hess and Thomas, 2019).

4. **Scalability and Production Costs**

   Scalability and production costs are also major

challenges in the development of artificial blood substitutes. Many of the technologies used to produce these substitutes, particularly stem cell-derived blood products, are expensive and labor-intensive (Pan *et al*.,2023). The process of scaling up production to meet the demands of widespread clinical use is further complicated by the need for quality control to ensure the safety and efficacy of each batch.

In addition to the high costs associated with manufacturing, the infrastructure required to produce and distribute artificial blood substitutes may be beyond the reach of many healthcare systems, particularly in low- and middle-income countries. Addressing these economic challenges is essential for the global accessibility of these life-saving technologies (Hess and Thomas, 2011).

2.4 Clinical Applications and Trials

Artificial blood substitutes hold significant potential for addressing a variety of clinical needs, especially in scenarios where traditional blood transfusions are not feasible or where blood supplies are limited. Over the past few decades, several clinical trials have been conducted to assess the efficacy, safety, and practical utility of various blood substitutes, including hemoglobin-based oxygen carriers (HBOCs), perfluorocarbon (PFC) emulsions, and synthetic oxygen carriers. While some trials have demonstrated promise, others have highlighted significant challenges, including toxicity, limited efficacy, and issues with scalability.

2.4.1 Summary of Recent Clinical Trials Involving Blood Substitutes

Recent clinical trials have focused on testing the safety and effectiveness of blood substitutes in a variety of medical contexts, including trauma care, surgical settings, and the management of chronic diseases. For example, a trial conducted on haemoglobin-based oxygen carriers (HBOCs) involved their use in trauma patients to determine if these substitutes could effectively replace donor blood in situations of extreme blood loss. The results were mixed; while HBOCs demonstrated a capacity to transport oxygen and reduce the immediate need for donor blood, they were associated with increased risks of complications such as vasoconstriction and hypertension (Schmidt, 2022).

In another clinical study, PFC emulsions were tested in surgical patients who were expected to experience significant blood loss. The trial showed that PFCs could enhance oxygen delivery to tissues, particularly under hypoxic conditions, but they required the administration of supplemental oxygen, limiting their applicability in settings where oxygen supply is constrained (Chang, 2018). Stem cell-derived red blood cells have also entered clinical trials. In a groundbreaking study, lab-grown red blood cells were transfused into a small group of volunteers, demonstrating the potential for these substitutes to function like natural blood (Spahn, 2020). However, larger-scale trials are needed to assess their long-term efficacy and safety.

2.4.2 Successes and Failures in Real-World Applications

The translation of artificial blood substitutes from laboratory research to real-world applications has been fraught with challenges. Several early HBOCs, such as HemAssist and PolyHeme, were tested in trauma and surgical patients. These products showed early promise in their ability to carry oxygen and avoid the need for blood typing. However, clinical trials revealed that these HBOCs often led to serious side effects, including kidney damage, increased mortality, and higher rates of stroke (Hillyer *et al*.,2021). As a result, many HBOCs were either discontinued or failed to gain regulatory approval.

Despite these setbacks, some successes have been reported. For instance, a newer generation of HBOCs, such as Hemopure, has shown more favorable outcomes in specific use cases, such as in patients with chronic anemia who cannot receive blood transfusions due to religious or medical reasons. Hemopure has been used in South Africa and Russia for patients with acute anemia, showing that it can temporarily replace blood and improve oxygen delivery without significant adverse effects (Spahn and Kocian, 2020). However, its use remains limited, and regulatory approval in major markets like the United States and Europe has yet to be achieved.

Perfluorocarbon emulsions, though not as widely tested as HBOCs, have seen some success in trials involving patients with traumatic brain injuries. In one study, patients receiving PFCs alongside supplemental oxygen showed improved outcomes in oxygen delivery to the brain and reduced mortality (Jahr *et al.,*2019). However, their widespread use is hindered by the need for an oxygen-enriched environment during administration, limiting their practicality in resource-limited or emergency settings (Pan *et al.,*2023).

2.4.3 Specific Use Cases (e.g., Trauma, Surgery, Chronic Diseases)

Artificial blood substitutes have been explored in several specific clinical contexts, each with varying degrees of success:

- **Trauma and Emergency Medicine:** Trauma settings, where rapid blood loss occurs, are one of the most critical areas of need for blood substitutes. HBOCs have been tested in these settings to provide immediate oxygen delivery when donor blood is unavailable. The goal is to stabilize patients long enough for them to reach a facility where they can receive a full transfusion. Despite their potential, HBOCs have faced significant regulatory challenges due to the increased risk of adverse cardiovascular events (Hess and Thomas, 2022). Nonetheless, trials continue to explore improved formulations that could mitigate these risks.
- **Surgical Applications:** In surgical settings, where blood loss is anticipated, blood substitutes could serve as a supplement to or replacement for donor blood. For example, PFC emulsions have been trialed in cardiac and orthopedic surgeries where oxygen delivery to tissues is critical. These emulsions have shown some success in reducing the need for transfusions (Schmidt, 2022), but they are not yet considered a complete alternative to donor blood due to limitations in their oxygen-carrying capacity and the need for supplemental oxygen.
- **Chronic Diseases and Anaemia Management:** Patients with chronic conditions such as anemia, particularly those who are not candidates for blood transfusion due to immune reactions or religious beliefs, represent another group for whom artificial blood substitutes could be life-saving. Hemopure, an HBOC, has been used in select cases for patients with chronic anemia. While it has shown promise in improving oxygenation and reducing symptoms of anemia, long-term safety data are still needed (Chang, 2018). Moreover, the high cost of production and regulatory hurdles remain obstacles to broader use.
- **Cancer Treatment and Chemotherapy:** Cancer patients undergoing chemotherapy often experience severe anemia and may require frequent blood transfusions. Artificial blood substitutes are being explored as a potential option to reduce the reliance on donor blood in this population. However, early trials have shown mixed results, with some products improving oxygen delivery but causing additional complications such as oxidative stress and organ dysfunction (Spahn, 2020).

Overall, while clinical trials have demonstrated the potential of blood substitutes in specific scenarios, the widespread adoption of these products remains limited by safety concerns, regulatory challenges, and production costs. Continued research and development are necessary to refine these technologies and make them viable options in routine clinical practice.

2.4.4 Comparative Analysis with Donor Blood

Artificial blood substitutes are often compared with traditional blood transfusions in terms of efficacy, cost-effectiveness, and patient outcomes. While traditional blood transfusions remain the gold standard in many clinical settings, the limitations of donor blood, such as supply shortages, the risk of disease transmission, and immunological reactions, have led to the development of artificial substitutes. This section provides a comparative analysis of these two options, examining their efficacy, cost-effectiveness, and the outcomes observed in patients.

2.5 Efficacy of Artificial Blood Substitutes vs. Traditional Blood Transfusion

The primary purpose of both donor blood and artificial blood substitutes is to transport oxygen to tissues, maintain volume, and support critical functions during hemorrhage or anemia. Donor blood, particularly packed red blood cells (PRBCs), is highly effective at oxygen transport due to the presence of haemoglobin within intact red blood cells. PRBC transfusions restore oxygen-carrying capacity and are able to bind and release oxygen in response to tissue needs (Hess, 2019). However, traditional blood transfusions come with risks, including the potential for haemolytic reactions, transfusion-related acute lung injury (TRALI), and the transmission of infectious agents such as hepatitis or HIV (Hillyer *et al*. 2021).

Artificial blood substitutes, such as Haemoglobin-Based Oxygen Carriers (HBOCs) and Perfluorocarbon (PFC) emulsions, aim to replicate the oxygen transport function of red blood cells but often fall short in efficacy when compared directly with donor blood. HBOCs, for example, can transport oxygen, but the free haemoglobin in these substitutes lacks the natural regulatory mechanisms of red blood cells. This leads to side effects like vasoconstriction due to nitric oxide scavenging, which can impair tissue perfusion (Winslow, 2018). PFC emulsions, while effective in oxygen delivery when used with supplemental oxygen, are limited in the amount of oxygen they can carry compared to hemoglobin in red blood cells (Riess, 2018). Therefore, while artificial blood substitutes offer the advantage of immediate availability and no need for blood typing, their overall oxygen transport efficacy remains inferior to that of donor blood.

Despite these limitations, artificial blood substitutes have shown potential in certain settings where donor blood is not available. For instance, in trauma cases where immediate oxygen delivery is crucial and donor blood is scarce, HBOCs have been used as a temporary solution until traditional transfusions can be administered (Silverman and Weiskopf,2021).

1. Cost-Effectiveness

Cost is a critical factor in the adoption of any medical technology, and artificial blood substitutes are no exception. Traditional blood transfusions, although highly effective, involve significant costs related to collection, testing, storage, and distribution. The need to ensure a continuous supply of safe, compatible blood, particularly in emergency situations, can strain healthcare resources (Schmidt, 2020). In contrast, artificial blood substitutes, particularly those that can be stored for extended periods, may offer logistical and financial advantages, especially in remote or resource-limited settings.

However, the cost of developing and producing artificial blood substitutes remains high. Technologies such as stem cell-derived blood products or recombinant haemoglobin are still in the experimental stages, with production costs significantly exceeding those of traditional blood (Chang, 2018). Additionally, the complex manufacturing processes and the need for rigorous testing to ensure safety contribute to the high price of these products. For instance, HBOCs like Hemopure are costly to produce and have faced setbacks in gaining widespread regulatory approval, further limiting their cost-effectiveness compared to donor blood (Pan *et al*., 2023).

Despite this, artificial blood substitutes may become more cost-effective as production techniques improve and economies of scale are achieved. Moreover, their potential to reduce the need for repeat transfusions in patients who develop antibodies against donor blood could make them a more financially viable option in specific clinical scenarios (Spahn and Kocian,2020).

2. Patient Outcomes

Patient outcomes are the ultimate measure of any medical intervention's success. Traditional blood transfusions have been extensively studied and are known to improve survival in patients experiencing severe haemorrhage, anemia, or undergoing major surgery (Hess and Shaz, 2019). In most cases, patients receiving PRBC transfusions show improved oxygenation,

reduced symptoms of anaemia, and overall better clinical outcomes. However, donor blood carries risks, including transfusion reactions, alloimmunization, and, although rare, the transmission of infectious diseases (Jahr and Walker, 2019).

Comparatively, artificial blood substitutes have shown mixed results in clinical trials. While they can provide temporary oxygenation in emergencies, they have not consistently demonstrated the same level of improvement in patient outcomes as donor blood. In trauma settings, for example, HBOCs have been used to stabilize patients, but the long-term outcomes have been less favorable due to complications like vasoconstriction and organ damage (Winslow, 2020). Similarly, PFC emulsions, while useful in specific cases of traumatic brain injury, require high oxygen concentrations to be effective, which can limit their broader applicability (Riess, 2021).

In patients with chronic conditions such as anemia, artificial blood substitutes like Hemopure have been used when traditional blood transfusions are not an option due to religious or medical reasons. These substitutes have been shown to improve oxygenation and reduce symptoms of anemia, but their long-term effects on survival and quality of life are still being studied (Chang, 2018). Additionally, in surgical settings, artificial blood substitutes have been used to reduce the need for transfusions, but their efficacy in improving patient outcomes compared to traditional blood remains limited (Schmidt, 2022).

The future of artificial blood substitutes may depend on overcoming current limitations in efficacy, reducing costs, and ensuring better patient outcomes. Continued research and clinical trials will be critical to improving these products and expanding their use in real-world medical settings.

2.6 Future Directions

The development of artificial blood substitutes is entering a new era characterized by advances in bioengineering, nanotechnology, and molecular techniques. These innovations promise to enhance the efficacy, safety, and versatility of artificial blood products, potentially revolutionizing transfusion medicine.

2.6.1 Advances in Bioengineering and Nanotechnology

Recent advancements in bioengineering and nanotechnology have opened new avenues for improving artificial blood substitutes. The integration of nanotechnology into the design of oxygen carriers allows for the creation of nanoparticles that can enhance the delivery of oxygen and nutrients at the cellular level. For instance, engineered nanoparticles can be designed to mimic the properties of red blood cells, enabling efficient oxygen transport while minimizing adverse effects (Kaur *et al.*, 2020). Research is underway to create biocompatible nanocarriers that can encapsulate oxygen molecules, thus improving stability and release profiles in various physiological conditions (Zhang *et al*., 2021).

Moreover, bioengineering techniques enable the modification of hemoglobin to enhance its therapeutic potential. Researchers are exploring ways to create cross-linked hemoglobin derivatives that maintain oxygen-binding capacity while reducing renal toxicity and vasoactive effects. These modified haemoglobins can be engineered to have a longer half-life in circulation, thereby increasing their effectiveness as oxygen carriers (Hockaday *et al*., 2020). The use of advanced materials science also supports the development of scaffolds for red blood cell production, providing a framework for stem cells to differentiate and mature into functional erythrocytes in vitro (Mooney *et al*., 2021). This method holds promise for addressing blood shortages by creating a sustainable source of red blood cells for transfusion.

2.6.2 Possibilities of Gene Editing and Other Molecular Techniques in Blood Production

Gene editing technologies, particularly CRISPR-Cas9, are emerging as powerful tools in the development of blood substitutes. These techniques allow for precise modifications of genes associated with hemoglobin production,

potentially leading to the generation of more effective artificial blood products (Gao *et al*., 2021). For example, gene editing could be used to create red blood cells with enhanced oxygen-carrying capacity or altered metabolic pathways that reduce the risks associated with transfusions, such as immune reactions or infections (Zhang *et al*., 2022).

Additionally, molecular techniques are being utilized to produce synthetic hemoglobin in bacterial or yeast systems. This approach not only increases yield but also facilitates the design of haemoglobin variants that can function optimally under different physiological conditions. By controlling the expression of specific genes, researchers can create haemoglobins that are less susceptible to denaturation, improving their stability and safety in clinical applications (Liu *et al*., 2020).

2.6.3 Potential for Personalized Artificial Blood Substitutes

Personalized medicine is increasingly recognized as a crucial component of modern healthcare, and the field of artificial blood substitutes is no exception. The ability to tailor blood products to individual patients' need holds great promise for improving outcomes and minimizing risks. Personalized artificial blood substitutes could be designed to match the unique haemoglobin profiles and oxygen transport requirements of different patients, particularly those with chronic conditions such as sickle cell disease or thalassaemia (Pereira *et al*., 2023).

Moreover, advancements in stem cell technology could allow for the development of patient-specific red blood cells derived from induced pluripotent stem cells (iPSCs). This approach would enable the production of compatible blood products without the risk of transfusion reactions or transmission of infectious diseases (Wang *et al*.,2022). The potential for using gene editing to correct specific genetic defects in a patient's own stem cells before differentiating them into red blood cells further enhances this personalized approach (Wang *et al*.,2021).

Conclusion

Artificial blood substitutes have made significant strides in recent years, addressing critical challenges in blood transfusion practices, including supply shortages and safety concerns associated with traditional donor blood. Current advancements in bioengineering, nanotechnology, and molecular techniques hold promise for developing safer and more effective alternatives, such as perfluorocarbon emulsions and hemoglobin-based oxygen carriers. Despite these advancements, challenges such as toxicity, stability, and regulatory hurdles remain significant barriers to widespread clinical application. Future research and development should focus on optimizing the efficacy and safety profiles of these products, exploring personalized approaches to meet individual patient needs, and leveraging innovative technologies like gene editing and stem cell-derived blood products. By addressing these needs, the potential of artificial blood substitutes can be fully realized, ultimately transforming transfusion medicine and improving patient outcomes.

References

Chang, T.M. (2018). Blood substitutes based on modified hemoglobin and hemoglobin microspheres. *Biomaterials*;**34(32)**:837-851.

Chang, T.M. (2018). Blood substitutes based on modified hemoglobin and hemoglobin microspheres. *Biomaterials*;**34(32)**:837-851.

Chang, T.M. (2018). Blood substitutes based on modified hemoglobin and hemoglobin microspheres. *Biomaterials*;**34(32)**:837-851.

Gao, X., *et al*. (2021). CRISPR-Cas9 technology: A novel approach for gene editing and its application in hematopoiesis. *Blood Review*; **35**:89-97.

Hess, J.R., Shaz, B.H., et al. (2019). Blood transfusion in critical care: Best practices and complications. *Transfusion*;**45(1)**:305-312.

Hess, J.R., Thomas, M.J. (2019). Blood use in war and disaster: Lessons from the past century. *Transfusion*;**43(2)**:1622-1633.

Hillyer, C.D., Shaz, B.H., Winkler, A.M., *et al.* (2021). Transfusion medicine and hemostasis: *Clinical and Laboratory Aspects*. 2nd ed. London: Elsevier; 2021.

Hillyer, C.D., Shaz, B.H., Winkler, A.M., *et al.* (2021). Transfusion medicine and hemostasis: Clinical and laboratory aspects.

2nd ed. London: Elsevier; 2021.
Hockaday, L.A., et al. (2020). Hemoglobin-based oxygen carriers: Biophysical properties and clinical applications. *Journal of Biomedical Materials Research*;**107(9)**:2062-2072.
Jahr, J.S., Walker, V., Manoochehri, K. (2019). Blood substitutes as pharmacotherapies in clinical practice. *Current Pharmacy Design*;**24(21)**:2460-2470.
Jahr, J.S., Walker, V., Manoochehri, K. (2022). Advances in synthetic blood substitutes: Recent progress and future directions. *Transfusion Medicine Review*;**36(4)**:210-220.
Kaur, K., Balaji, S., Dhanaraj, A. (2020). Nanotechnology in the development of blood substitutes: Recent advancements and future prospects. *Nanomedicine*;**15(4)**:349-368.
Liu, S., et al. (2020). Synthetic hemoglobin production in microbial systems: Progress and prospects. *Biotechnology Advances*; **38**:107414.
Mooney, D.J., *et al.* (2021). Biomaterials for blood cell generation: Scaffolding stem cell development. *Journal of Material Chemistry B*.;**9(6)**:1151-1165.
Pan, R., Lu, J., Han, Y. (2023). Red blood cell substitutes: From concept to reality. *Journal of Material Chemistry B*.;**11(7)**:1167-1182.
Parapia, L.A. (2020). History of blood transfusion. *British Journal of Haematology*;**150(1)**:1-6.
Pereira, M.J., et al. (2023). Personalized artificial blood substitutes: Meeting individual patient needs. *Transfusion*;**63(7)**:1870-1880.
Riess, J.G. (2018). Oxygen carriers ("blood substitutes")—raison d'être, chemistry, and some physiology. *Chemistry Review*;**101(9)**:2797-2920.
Riess, J.G. (2021). Nanoparticles as oxygen carriers: A new frontier for blood substitutes. J *Nanobiotechnology*;**19(1)**:134-140.
Schmidt, P.J. (2022). The role of PFC emulsions in surgery: Progress and limitations. *Journal of Surgical Research*;**67(2)**:315-324.
Schmidt, P.J. (2019). Karl Landsteiner and the discovery of the blood groups. *Transfusion Medicine Review*;**15(3)**:103-106.
Silverman, T.A., Weiskopf, R.B. (2021). Hemoglobin-based oxygen carriers: Current status and future directions. *Anesthesiology*;**100(3)**:1227-1236.
Spahn, D.R., Kocian, R. (2020). Artificial oxygen carriers: A new future? *Critical Care*;**24(2)**:689-699.
Wang, H., et al. (2022). Induced pluripotent stem cells in transfusion medicine: Current applications and future directions. *Blood Review*; **45**:100738.
Wang, Y., et al. (2021). Gene editing strategies for creating patient-specific blood products. Stem Cells *Translation Medicine*;**10(11)**:1553-1564.
Winslow, R.M. (2018). Hemoglobin-based oxygen carriers: An overview of history, clinical trials, and pathophysiology. *Transfusion*;**89(4)**:192-202.
Winslow, R.M. (2020). Current status of oxygen carriers ("blood substitutes"): 2020 update. *Vox Sanguine*;**89(4)**:192-202.
Zhang, C., *et al.* Gene editing for enhanced hemoglobin production: Opportunities and challenges. *Gene Therapy*;**29(1)**:4-16.
Zhang, Q., Wang, Y., Wu, Y., *et al.* (2021). Engineering nanoparticles for improved oxygen delivery in the treatment of hypoxic conditions. *Biomed Microdevices*;**23(2)**:15-24.

Citation: Moore-Igwe, B.W. and Wenah-Emmanuel, J.E. Artificial Blood Substitutes: An Update on Strategies For Blood Transfusion Alternatives. ***Sokoto Journal of Medical Laboratory Science*; 9(4): 135 – 144.** https://dx.doi.org/10.4314/sokjmls.v9i4.16